HEMASATE ULTRA HS3125 6.24 G
CALCIUM CHLORIDE : 6.24 G DEXTROSE : 49.5 G POTASSIUM CHLORIDE : 10.1 G CITRIC ACID : 7.18 G SODIUM CHLORIDE : 263 G MAGNESIUM CHLORIDE : 2.14 G · DIN 02422603 · CHIEF MEDICAL SUPPLIES LTD
Health Canada status: APPROVED
What is HEMASATE ULTRA HS3125?
HEMASATE ULTRA HS3125 6.24 G contains CALCIUM CHLORIDE : 6.24 G DEXTROSE : 49.5 G POTASSIUM CHLORIDE : 10.1 G CITRIC ACID : 7.18 G SODIUM CHLORIDE : 263 G MAGNESIUM CHLORIDE : 2.14 G. It is listed in the Health Canada Drug Product Database under DIN 02422603, held by CHIEF MEDICAL SUPPLIES LTD, supplied as SOLUTION for HAEMODIALYSIS administration. Health Canada currently lists it as approved, status dated 11-Mar-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02422603 |
|---|---|
| Brand name | HEMASATE ULTRA HS3125 |
| Generic / active ingredient | CALCIUM CHLORIDE : 6.24 G DEXTROSE : 49.5 G POTASSIUM CHLORIDE : 10.1 G CITRIC ACID : 7.18 G SODIUM CHLORIDE : 263 G MAGNESIUM CHLORIDE : 2.14 G |
| Manufacturer | CHIEF MEDICAL SUPPLIES LTD |
| Strength | 6.24 G |
| Dosage form | SOLUTION |
| Route of administration | HAEMODIALYSIS |
| Schedule | Ethical |
| ATC code | B05ZA HEMODIALYTICS, CONCENTRATES |
| AHFS class | 38:00.00 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 11-Mar-2014 |
| Original market date | 2014-04-07 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B05ZA HEMODIALYTICS, CONCENTRATES. 117 of 588 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACID CONCENTRATE 2156 | 10.1 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02239491 |
| ACID CONCENTRATE 2182 | 262.98 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02210835 |
| ACID CONCENTRATE A1221 | 3.35 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254344 |
| ACID CONCENTRATE A1222 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254336 |
| ACID CONCENTRATE A1223 | 9.92 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254328 |
| ACID CONCENTRATE A1224 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254301 |
| ACID CONCENTRATE A1225 | 263.0 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254298 |
| ACID CONCENTRATE A1226 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254255 |
| ACID CONCENTRATE A1227 | 8.27 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254247 |
| ACID CONCENTRATE A1228 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02533774 |
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.